“PanCancer” panel (APC, FOXA1, RASSF1A) detected cancer with 72.4% sensitivity, 73.5% specificity and 72.8% accuracy.“CancerType” panel (SCGB3A1, SEPT9, and SOX17) discriminated TOO with 80.0%, 98.9%, and 85.1% specificity for breast, colorectal, and lung cancer, respectively. This evidence concerns the gene SOX17 and lung carcinoma.